Ticker Search:  Getting Started | Register | Videos | Newsletter | Partners | Login    

Basics
Exelixis, Inc. Common Stock
Exelixis Inc is a biotechnology company. It is involved in discovery, development, and commercialization of new medicines for people with cancer. The Cabometyx product generates maximum revenue for the company.
IPO Date: May 1, 2000
Sector: Healthcare
Industry: Biotech
Market Cap: $12.02B
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.25 | 2.20%
Avg Daily Range (30 D): $0.84 | 1.86%
Avg Daily Range (90 D): $0.68 | 1.66%
Institutional Daily Volume
Avg Daily Volume: 2.05M
Avg Daily Volume (30 D): 2.27M
Avg Daily Volume (90 D): 2.38M
Trade Size
Avg Trade Size (Sh.): 161
Avg Trade Size (Sh.) (30 D): 62
Avg Trade Size (Sh.) (90 D): 65
Institutional Trades
Total Inst.Trades: 11,739
Avg Inst. Trade: $2.85M
Avg Inst. Trade (30 D): $6.39M
Avg Inst. Trade (90 D): $5.29M
Avg Inst. Trade Volume: .16M
Avg Inst. Trades (Per Day): 3
Market Closing Trades
Avg Closing Trade: $6.58M
Avg Closing Trade (30 D): $27.07M
Avg Closing Trade (90 D): $21.32M
Avg Closing Volume: 325.3K
   
News
Jul 20, 2025 @ 10:30 AM
Here's Why This $50 Healthcare Stock Could Be the ...
Source: Prosper Junior Bakiny
Jul 19, 2025 @ 10:09 AM
After Falling 68%, Where Will This Weight-Loss Dru...
Source: James Brumley
Jul 8, 2025 @ 2:25 PM
Amid NCI Budget Fears, Emerging Oncology Stocks Ga...
Source: Prnewswire
May 18, 2025 @ 8:06 PM
CoreWeave, Super Micro Computer And Coinbase Are A...
Source: Lekha Gupta
May 14, 2025 @ 6:43 PM
Tech Stocks Edge Up, AMD Rallies 5%, 30-Year Yield...
Source: Piero Cingari
Financials
  TTM Q1 2026 FY 2024
Basic EPS $.57 $1.8
Diluted EPS $.55 $1.76
Revenue $ $ 555.45M $ 2.17B
Gross Profit $ $ 536.28M $ 2.09B
Net Income / Loss $ $ 159.62M $ 521.27M
Operating Income / Loss $ $ 186.86M $ 604.62M
Cost of Revenue $ $ 19.17M $ 76.22M
Net Cash Flow $ $ -33.62M $ -45.62M
PE Ratio